Benign Prostatic Hyperplasia Treatment Equipment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End user, By Region & Competition, 2021-2031F

The Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market is projected to expand from USD 11.56 Billion in 2025 to USD 14.98 Billion by 2031, reflecting a compound annual growth rate of 4.41%. This market comprises medical devices employed for both the minimally invasive and surgical management of enlarged prostate glands, including technologies such as resectoscopes, laser systems, and radiofrequency ablation devices. The primary catalysts driving this growth are a rapidly aging global population and a rising preference for minimally invasive procedures that facilitate faster patient recovery, a demand heavily influenced by the high incidence of BPH among older men. For instance, the American Urological Association reported in 2024 that the prevalence of benign prostatic hyperplasia and related lower urinary tract symptoms in men aged 65 and older ranged between 29% and 35%.

Despite these positive demand metrics, a major obstacle hindering broader market expansion is the significant capital expenditure necessary for advanced surgical technologies. The high costs associated with acquiring and maintaining modern laser consoles and robotic systems can restrict adoption rates, particularly within healthcare facilities operating with tight procurement budgets. Consequently, this financial barrier frequently compels providers in cost-sensitive areas to depend on traditional, less efficient methodologies, thereby decelerating the penetration of newer equipment solutions.

Market Driver

The rising prevalence of benign prostatic hyperplasia is fundamentally propelled by the rapid aging of the global male population, requiring a sustained increase in the deployment of diagnostic and therapeutic equipment. As life expectancy increases, the number of patients needing intervention for lower urinary tract symptoms grows, necessitating that healthcare providers upgrade their urology departments to address this predictable and expanding addressable market for resectoscopes and ablation systems. According to the United Nations' "World Population Prospects 2024: Summary of Results" published in July 2024, the proportion of the global population aged 65 years or older is expected to increase to nearly 16% by 2050, significantly widening the primary demographic susceptible to prostate enlargement.

Alongside demographic changes, there is a distinct surge in demand for minimally invasive and non-surgical treatment options, driven by patient preference for procedures that offer reduced recovery times. This trend is steering the market toward advanced technologies, such as robotic-assisted waterjet ablation and prostatic urethral lift devices, and away from traditional transurethral resection, leading to substantial adoption rates for companies specializing in these platforms. For example, PROCEPT BioRobotics reported in February 2024 that revenue for their robotic systems reached $136.2 million for the fiscal year 2023, an 82% increase over the prior year, while Boston Scientific reported net sales of $1.95 billion for their Urology and Pelvic Health segment in 2023, further validating this technological uptake.

Market Challenge

The primary challenge inhibiting the growth of the Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market is the substantial capital expenditure required for advanced surgical technologies. The significant acquisition and ongoing maintenance costs linked to modern laser consoles and robotic systems establish a formidable financial barrier to adoption, requiring healthcare facilities with constrained budgets to critically assess the return on investment for such capital-intensive equipment. When the upfront costs are balanced against hospital financial realities, many providers are forced to defer purchases and continue relying on traditional, less expensive methodologies like transurethral resection, which stalls the market penetration of more efficient solutions.

This difficulty in justifying high-value acquisitions is further aggravated by tightening reimbursement structures that diminish available capital for reinvestment. According to the American Urological Association, the Medicare Physician Fee Schedule conversion factor was reduced by approximately 3.37% in 2024, dropping to $32.74 from the previous year. Such reductions in payment rates directly affect the revenue streams of urology practices and hospitals, significantly restricting their ability to absorb the high costs associated with advanced BPH treatment systems and directly impeding market expansion.

Market Trends

The integration of Artificial Intelligence into Robotic Aquablation Systems marks a transformative shift, elevating procedural precision beyond human limitations by embedding machine learning algorithms into robotic consoles to optimize treatment planning and real-time tissue resection. This technology leverages extensive datasets of anatomical imagery to assist surgeons in mapping prostate contours, thereby improving safety and consistency during waterjet ablation. For instance, PROCEPT BioRobotics announced in August 2024 the FDA clearance of the HYDROS Robotic System, an AI-powered platform that utilizes insights from over 50,000 real-world procedures to provide advanced image guidance and predictive workflows for treating benign prostatic hyperplasia.

Concurrently, the commercialization of Temporary Implantable Nitinol Devices is reshaping minimally invasive therapies by providing symptom relief without the need for permanent implants or causing thermal damage. These devices, which temporarily reshape the prostatic urethra, are becoming increasingly popular due to their ability to preserve sexual function and facilitate rapid recovery in outpatient settings, leading market players to aggressively secure contracts to ensure accessibility. Highlighting this trend, Olympus announced in March 2024 that its temporary nitinol device had secured placement on 13 Group Purchasing Organization contracts in the United States, significantly broadening the commercial reach of this non-permanent therapeutic option.

Key Market Players

• Urologix, LLC
• Olympus Corporation
• Boston Scientific Corporation
• Teleflex Incorporated
• Zenflow Inc.
• Sonablate Corporation
• Richard Wolf Gmbh
• Karl Storz SE
• Terumo Medical Corporation

Report Scope

In this report, the Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market, By Type

• Laser-based Equipment
• Microwave-based Equipment
• Radiofrequency-based Equipment
• Other

Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market, By End user

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market.

Available Customizations:

Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).